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Abstract 
 
Leunca (Solanum nigrum L.)ethanolic extractshowedcytotoxic activity on several cancer 
cell lines (HepG2, HT-29) and showed anti-proliferative activityon MCF-7 cells. Its application 
as a combinationagent in chemotherapy will increase the effectivity and reduce the toxicity of 
chemotherapy. We predict that application of combinatorial chemotherapy in cancer treatment 
will be more effective and less toxic compared to single treatment. Our research aims to 
investigate the cytotoxic activitiy of leunca herbs ethanolic extract alone and in combination 
with doxorubicin on HeLa cell line. MTT assay was conducted to measure the growth 
inhibitory effect of leunca herbs ethanolic extract and combinatorial treatments. Leunca herb 
ethanolic extract (5, 50, 250 μg/ml) increased the cytotoxic effect of  doxorubicin compared to 
doxorubicin alone. The strongest cytotoxic activity resulted from the combination of 250 μg/ml 
leunca herbs ethanolic extract and 250 nM doxorubicin. Based on our results, leunca herbs 
ethanolic extract is a potential chemopreventive agent, while its molecular mechanism needs to 
be explored. 
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INTRODUCTION 
 
Combination chemotherapy (co-
chemotherapy) has been used widely due to tumor 
cell heterogeneity, drug resistance, and the 
increasing successfulness in the clinic (Kufe et al., 
2003). Chemoprevention agents originated from 
nature seems to be a promising candidate for co-
chemotherapeutic agents. Leunca (Solanum 
nigrum L.) is one of the herbs having this potency. 
It has solanine, solasodine, and solamargine 
(Everist, 1974; Weller and Phipps, 1979). 
Solanine is able to induce apoptosis in 
HepG2 cells mediated by the inhibition of Bcl-2 
expression (Ji et al., 2008). While β-2-solamargine 
is cytotoxic on some cancer types, e.g.: colon 
cancer (HT-29 and HCT-15), prostate cancer 
(LNCaP and PC-3), and breast cancer (T47D and 
MDA-MB-231) (Hu et al., 1999). Solamargine 
could also induce apoptosis through mitochondrial 
pathway (Liang et al., 2008) and modulate the 
expressions of TNFRs and Bcl-2 on H441, H520, 
H661, and H69 human lung cancer cells (Liu et al., 
2004). Thus, its potential as co-chemotherapeutic 
agent needs to be explored.  
Leunca herb ethanolic extract has been 
found to have synergistic effect when combined 
with doxorubicin on T47D cells (Anindyajati et 
al., 2010) as well as with cisplatin on HeLa cells 
(Istiaji et al., 2010). This study aimed to observe 
the effect of leunca’s ethanolic extract (LEE) 
application on the cytotoxicity performed by 
doxorubicin, analyzed by MTT assay.  
The data could complete the co-
chemotherapeutic potency of leunca. 
Combinatorial treatment of doxorubicin and LEE 
were applied in order to increase the cytotoxicity 
of doxorubicin on HeLa cells, allowing the use of 
lower dose of the chemotherapeutic agent giving 
less toxicity on normal tissues. 
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MATERIALS AND METHODS 
 
Sample preparation  
Dried powder of leunca herbs were 
purchased from Balai Besar Penelitian dan 
Pengembangan Tanaman Obat dan Obat 
Tradisional (B2P2TOOT), Indonesia. Dried 
powder was then extracted by maceration for 5 
days with 70% ethanol. Collected filtrate was 
concentrated using rotary evaporator (Heidolph 
WB2000), then dissolved in Dimethyl Sulfoxide 
(DMSO) (Sigma). Both 5mg/ml doxorubicin and 
extract solution were diluted in DMEM cell culture 
medium before being applied. DMSO was used as 
the co-solvent in dissolving LEE in DMEM culture 
medium. 
 
Chemicals 
Dulbecco’s Modified Eagle Medium 
(DMEM) powder (Gibco), 10%
v
/vFetal Bovine 
Serum (FBS) (Gibco), and 10,000 units/ml 
Penicillin-10,000 μg/ml Streptomycin (Gibco) 
were used for cell culture medium. Cells were 
harvested using 25%Tripsin EDTA (Gibco). For 
cytotoxicity assay, 10%
v
/vSodium Dodecyl 
Sulphate (SDS) (Merck) dissolved in 0.1N HCl 
(Merck) as stopper reagent, and 3-[4,5-dimethyl 
thiazole-2-y(-2,5- diphenyl tetrazolium bromide)] 
(MTT) dissolved in PBS as MTT reagent were 
used. 
 
HeLa cells 
HeLa cells being used were from the 
collection of Cancer Chemoprevention Research 
Center (CCRC), Universitas Gadjah Mada. The 
cell line was a gift from Prof. Tatsuo Takeya, Nara 
Institute of Science and Technology (NAIST), 
Japan. 
 
Cytotoxicity and combinatorial assay 
MTT cytotoxicity assay was used to 
examine the effect of LEE alone and in 
combination with doxorubicin on HeLa cells. 
5x10
3
HeLa cells/well was distributed into 96-well 
plate (Iwaki) and incubated in 37˚C with 5% CO2 
(Heraeus) for 24 hours. In combinatorial assay, 
concentration of 5, 50, and 250µg/ml for LEE and 
100, 250nM for doxorubicin were used. After 24 
hours incubation, MTT reagent was applied, 
followed by 4 hours incubation. 10% 
v
/v SDS in 
0.1N HCl as stopper reagent was then applied. 
Plate was then kept with protection from light 
overnight, continued with absorbance 
determination (λ 595 nm) using ELISA reader 
(Bio-Rad). 
 
Analysis 
The cells’ viability was calculated based on 
the formula as follow: 
 
% viability =                                                        x 100% 
 
The cells’ viability of LEE combined with 
doxorubicin treated cells then compared to LEE 
treated alone. 
 
RESULTS AND DISCUSSION 
 
Single and combinatorial treatment of LEE 
and doxorubicin on HeLa cells gave the viability 
shown in Table I, and being plotted in diagram 
(Fig. 1). It was shown that four concentration of 
combinations shows synergism on HeLa cells, 
represented with less cells’ viability of 
combinatorial treatment compared to single 
treatment. 
Cells’ morphology after treatment was also 
observed (Fig. 2). Treatment of LEE or 
doxorubicin alone led to cells’ morphological 
change pointed by white arrows, respectively (Fig. 
2(b) and 2(c)). Combination of them caused more 
changes compared to single treated cells (Fig. 
2(d)). While control cells showed no changing in 
cells’ morphology representing cells’ death (Fig. 
2(a)). Hence, synergism of combinatorial treatment 
was observed. 
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Table I. Cell viability (%) of single and combinational treatment of LEE and doxorubicin on HeLa cells 
 
LEE concentration (µg/ml) Doxorubicin (nM) 
0 100 250 
0 100 102.49 99.33 
5 110.47 107.98 92.68 
50 99.50 85.62 86.28 
250 64.51 65.84 46.97 
 
 
 
 
 
Figure 1.  Combinational effect of LEE and doxorubicin. Test were carried out by incubating 5x103 MCF-7 
cells/well with concentration 50 µg LEE/ml, 250 µg LEE/ml, and doxorubicin 100 nM, 250 nM for 
24 hours. After 24 hourd, cell were added by MTT reagent to obtain the absorbance representing 
cell viability. Combination treatment of LEE 250 µg/ml and doxorubicin 250 nM give optimal 
reduction of cell viability.   
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 2.  Combination of doxorubicin and LEE showed synergism on HeLa cells; (a) cell control; 24-
hours treatment of (b) 250 µg/ml LEE; (c) 250nMdoxorubicin; (d) 250nM doxorubicin in 
combination with 250 µg/ml LEE. Treatment of LEE and doxorubicin alone brought cells to 
death, shown by change in cells’ morphology pointed by white arrows, respectively (b and c). 
Combination of them caused more cells’ death compared to single treated cells (d), showing 
synergism. While control cells showed no change in cells’ morphology (a). Observation was 
done by using inverted microscope at 300x magnification. 
 
 
Leunca ethanolic extract alone is cytotoxic 
against HeLa cells with IC50 227μg/mL (Istiaji et 
al., 2010). When it is combined with doxorubicin, 
it performed synergistic effect. The cells’ viability 
is decreasing compared to LEE treated cells, 
meaning that the combination gave inhibition of 
HeLa cells’ growth. LEE may contain solanine and 
solamargine (Everist, 1974; Weller and Phipps, 
1979). Solanine and β-2-solamargine suppress Bcl-
2 expression (Ji et al., 2008; Liu et al., 2004). Bcl-
2 is an antiapoptotic protein. Overexpression of 
Bcl-2 prevented the efflux of cytochrome c from 
the mitochondria and the initiation of apoptosis 
(Yang et al., 1997). When it suppressed, cells will 
undergo apoptosis easier. Cytosolic cytochrome c 
will be larger when Bcl-2 is down regulated. This 
will lead to initiation of apoptosis (Yang et al., 
1997). Liang et al. (2008) also proved that β-2-
solamargine induced apoptosis through 
mitochondrial pathway, rendering the correlation 
between Bcl-2 suppression and apoptosis induction 
via classical pathway. The TNFRs induction on 
lung cancer cells (Liu et al., 2004) probably could 
be other mechanism on HeLa cells’ growth 
inhibition. The molecular targeted protein of LEE 
should be determined briefly. 
The combination of LEE and doxorubicin 
exhibited synergism on inhibition of HeLa cells’ 
growth. To have the same number of cells’ 
viability, we’ll need less doxorubicin. This will 
lessenside effects as well as less resistance 
phenomenon found in cancer cells treated with 
chemotherapeutic agent (Kufe et al., 2003). 
Synergism of the combination possibly happened 
due to the ability of LEE to induce apoptosis by 
different mechanism with doxorubicin. 
Doxorubicin inhibits topoisomerase II activity 
(Potter and Rabinovitch, 2005), while LEE induces 
apoptosis via its solanine and solamargine 
activities. Further study needs to be conducted to 
determined molecular mechanism underlying this 
activity.  
 
CONCLUSION 
 
We can conclude that LEE has synergism 
activity when combined with doxorubicin on HeLa 
cells. 
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